Protocols
10 protocol(s) meet the specified criteria
Drug: Nivolumab
Protocol No.TitleStatus
CA209-274A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial CarcinomaOpen
CO-338-087/ATHENAA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based ChemotherapyOpen
DFCI17-064/OMNIVOREPhase II study of Optimized Management of NIVOlumab based on REsponse in patients with advanced renal cell carcinoma (OMNIVORE study)Open
EA2165-CIRBA Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal CancerOpen
EA8143-PROSPER A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) Open
LCCC1626Phase Ib/II Study Of IV Nivolumab And Intrapleural Talmogene Laherparepvec For Patients With Malignant Pleural Effusion Open
LCCC1632Phase II Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal AdenocarcinomaOpen
MIRATI-516-003A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial CarcinomaOpen
NCI-10057-CIRBA Phase II Study of Talimogene Iaherparepvec Followed by Talimogene Iaherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin TumorsOpen
S1616-CIRBA Phase II Randomized Study of Nivolumab (NSC-732442) With Ipilimumab (NSC-748726) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 AgentOpen